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Abstract
OBJECTIVE—The objectives of the study was to determine whether salivary progesterone (P) or
estriol (E3) concentration at 16–20 weeks’ gestation predicts preterm birth or the response to 17α-
hydroxyprogesterone caproate (17OHPC) and whether 17OHPC treatment affected the trajectory of
salivary P and E3 as pregnancy progressed.
STUDY DESIGN—This was a secondary analysis of a clinical trial of 17OHPC to prevent preterm
birth. Baseline saliva was assayed for P and E3. Weekly salivary samples were obtained from 40
women who received 17OHPC and 40 who received placebo in a multicenter ran-domized trial of
17OHPC to prevent recurrent preterm delivery.
RESULTS—Both low and high baseline saliva P and E3 were associated with a slightly increased
risk of preterm birth. However, 17OHPC prevented preterm birth comparably, regardless of baseline
salivary hormone concentrations. 17OHPC did not alter the trajectory of salivary P over pregnancy,
but it significantly blunted the rise in salivary E3 as well as the rise in the E3/P ratio.
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CONCLUSION—17OHPC flattened the trajectory of E3 in the second half of pregnancy, suggesting
that the drug influences the fetoplacental unit.
Keywords
17-alpha-hydroxyprogesterone caproate; longitudinal studies; preterm birth; salivary estriol; salivary
progesterone
Progesterone has long been recognized as necessary for pregnancy maintenance, and the role
of progesterone withdrawal in the initiation of labor in animal species has been known for
decades.1 However, the role of progesterone withdrawal, as measured by plasma progesterone
concentration or the ratio of progesterone/estrogens, in the initiation of normal labor in humans
or other primates is unclear.2-4 Nevertheless, there is evidence that functional progesterone
withdrawal caused by changes such as reduction in progesterone receptors5 or relative increase
in the progesterone receptor (PR)-A progesterone receptor isoform, which blocks PR-B
isoform-mediated gene transcription6 may trigger labor in humans. We are unaware of any
study that has assessed the ability of measurement of salivary progesterone, which is
representative of the biologically active unbound fraction in plasma or serum,7 to predict
preterm birth.
In 2 recent randomized clinical trials, injections of 17-α-hydroxyprogesteronecaproate
(17OHPC)8 or vaginal suppositories containing progesterone9 reduced the recurrence or
occurrence of preterm birth among high-risk women. Because 17-α-hydroxyprogesterone is
produced by the normal placenta in amounts greater than the doses administered in these
clinical trials10 and because normal plasma progesterone concentrations are 9 times higher than
those of 17-α-hydroxyprogesterone11 and greater than the dissociation constant of the
progesterone receptor,12 the mechanism for this preventive effect is uncertain. If these drugs
worked by counteracting mild progesterone deficiency, then one might hypothesize them to
be more effective among women with lower salivary progesterone concentrations at the start
of treatment or that these drugs would modify the change in progesterone concentrations as
pregnancy progressed.
We therefore conducted this secondary analysis of our previously published 17OHPC trial8 to
test the hypotheses that the concentration of progesterone in saliva, measured at 16–20 weeks’
gestation, can be used to predict which women will deliver at less than 37 weeks’ gestation;
that women with low salivary progesterone concentration at baseline will be more likely to
benefit from 17-α-hydroxyprogesterone caproate injections; and that compared with placebo,
treatment with 17OHPC will cause a more rapid rise in progesterone concentration as
pregnancy progressed.
Materials and Methods
This is a secondary analysis from Maternal-Fetal Medicine Units Network randomized, double-
masked, placebocontrolled clinical trial of 17-α-hydroxyprogesterone caproate to prevent
recurrent preterm birth, the methods and results of which have been reported previously.8 In
summary, the trial enrolled 463 women with at least 1 previous spontaneous preterm delivery
and randomized them to receive weekly injections of 17-α-hydroxyprogesterone caproate (n
= 310) or castor oil placebo (n = 153) beginning at 16 to 206/7 weeks’ gestation, confirmed by
sonography, and continuing until 36 weeks 6 days’ gestation. The trial demonstrated a
reduction in recurrent preterm birth from 54.9% in the placebo group to 36.3% in the treatment
group.
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As part of the trial protocol, saliva specimens for estriol and progesterone were collected from
the women immediately before receipt of the initial injection and then each week until 36 weeks
6 days, prior to receipt of the weekly injection. All samples were collected between 9 AM and
8 PM and were taken approximately 1 week after receipt of 17OHPC. Women were asked to
refrain from eating, drinking, smoking, chewing gum, tooth brushing, or flossing for 1 hour
before the visit and to rinse their mouths with water 10 minutes before collecting the sample.
The women could also collect the sample at home, following the same procedure. Samples
were stored at room temperature for up to 48 hours and then at −80°C.
Total salivary estriol was assayed using the SalEst (Adeza Inc, Sunnyvale, CA) enzyme-linked
immunosorbent assay test kit, following the manufacturer’s instructions. The test sensitivity
was 0.19 ng/mL, within and between batch coefficients of variation were generally 10% or
less, and there was negligible cross-reactivity with steroids other than estriol and its conjugates.
13 Total progesterone was assayed with the Salimetrics (Salimetrics LLC, State College, PA)
salivary progesterone competitive enzyme immunoassay kit, according to the manufacturer’s
recommendations. The test sensitivity was 5 pg/mL, and the intra- and interas-say coefficients
of variation were both less than 10%. Cross-reactivity with other steroids was negligible. In
particular, cross-reactivity with 17-α-hydroxyprogesterone was 0.07%. All assays were
performed by Adeza, Inc.
Gestational age at birth, in completed weeks, was determined from the sonographically-
confirmed gestational age at randomization and the time elapsed from randomization to birth;
for the analysis of baseline concentrations, preterm (< 37 completed weeks) birth was the
outcome of interest, with delivery at less than 35 and less than 32 weeks as secondary outcomes.
Continuous variables were compared using the Wilcoxon rank-sum test and categorical
variables were compared using the χ2 test. When categories were ordered, significance was
assessed with the Cochran-Armitage test for trend.14 Multiple logistic regression was used to
adjust the association between baseline salivary estriol or progesterone and preterm birth for
gestational week when the sample was obtained and treatment group. To determine whether
the effectiveness of treatment differed according to baseline estriol or progesterone, women
were stratified by whether their concentration was low (< 25%), midrange (25–75%), or high
(> 75%), and rate of preterm birth was compared between the treatment and control groups
within each stratum in 2-by-3 tables. We used the Breslow-Day test15 to determine whether
treatment effect differed significantly by baseline salivary steroid concentrations.
The clinical trial included 463 women who contributed 6305 samples for progesterone (462 of
whom contributed 6298 samples for estriol). Analyses of baseline hormone levels were
restricted to women who provided these samples in sufficient volume (413 women for estriol
and 386 for progesterone); those with missing samples did not differ significantly from those
with samples available for both assays on any of the characteristics in Table 1. The analysis to
determine whether treatment with 17OHPC modified the normal longitudinal change in
salivary hormones was restricted to women who collected a salivary sample in all eligible
weeks and whose visits were on schedule (ie, within 5–10 days of each other). There were 157
such women, who were more likely than other women in the trial to be white (P = .002) and
older (P for trend = .007). However, there were no significant differences in treatment group,
preterm birth in the treated pregnancy, gestational age at the start of treatment, the number of
previous spontaneous preterm births, body mass index, years of education, or smoking status.
From among the 157 women with on-schedule visits, we randomly selected 20 women who
received 17OHPC and delivered preterm, 20 who received 17OHPC and delivered at term, 20
who received placebo and delivered preterm, and 20 who received placebo and delivered at
term; the number was based on available resources rather than a formal sample size estimate.
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These 80 women contributed a total of 1244 saliva samples for the study of estriol and 1158
for progesterone. The longitudinal analysis used mixed models to account for the
nonindependence of multiple hormone measures obtained on each woman. To determine
whether 17OHPC affected the trajectory of salivary hormones, we modeled the salivary
hormone levels as a function of treatment (17OHPC vs placebo), gestational age (as a linear
term), and the interaction of treatment and gestational age. Statistical significance of this
interaction term would indicate that the trajectory of salivary hormone with advancing
gestational age differed between the 17OHPC and placebo groups. The primary study protocol,
including collection and analysis of the saliva samples, was approved by the institutional review
boards of the clinical sites and the Biostatistical Coordinating Center, and all women provided
written informed consent.
Results
Among the 413 women with baseline samples, 170 (41%) gave birth to a preterm infant.
Because the beneficial effect of 17OHPC was similar, regardless of baseline salivary
progesterone or estriol (see below), the treated and placebo groups were combined in the
analysis of the association between baseline hormones and preterm birth. The association
among various characteristics of the women and salivary hormone concentrations and preterm
birth are presented in Table 1. In this high-risk population, only gestational age at specimen
collection was statistically significantly associated with salivary estriol (P < .001) and
progesterone (P = .02); the levels of both hormones were higher at later gestational ages.
Progesterone levels decreased with advancing maternal age, but the association was of
borderline statistical significance (P = .09). All other factors in the table were not associated
with either hormone measurement (all P > .20). In addition, as has been previously described,
16 the only characteristic associated with preterm birth in the study pregnancy was the number
of previous preterm births. Compared with women with a history of a single preterm birth,
those with more than 1 previous preterm birth were at increased risk.
The median baseline salivary progesterone concentration among women who delivered
preterm was 488 pg/mL (25th to the 75th percentile 319–724), compared with 446 pg/mL (25th
to the 75th percentile 318–619) among women who delivered at term (P = .08). The
corresponding values for estriol were 0.40 (0.2–0.5) ng/mL and 0.40 ng/mL (0.2-0.5; P = .94).
The association between low, mid, and high salivary concentrations of steroid hormones and
preterm birth at different gestational ages is presented in Table 2.
There were tendencies for both high and low values of both salivary progesterone and estriol
to be associated with increased occurrence of preterm birth, although only the associations
between low salivary estriol and birth at less than 35 and less than 32 weeks’ gestation, and
high progesterone and birth at less than 35 weeks’ gestation were statistically significant.
Associations between salivary hormones and spontaneous preterm birth were in the same
direction as the associations with total preterm birth but were virtually always of smaller
magnitude. Only the association between estriol less than the 25th percentile and spontaneous
preterm birth less than 32 weeks was statistically significant (odds ratio, 2.0; 1.02-3.9). Neither
high (> the 75th percentile) nor low (< the 25th percentile) baseline estriol/progesterone ratio
was significantly associated with total or spontaneous preterm birth at less than 37, less than
35, or less than 32 weeks’ gestation.
Adjustment for gestational age at sample collection and treatment assignment had minimal
impact on the results, but after adjustment only the odds ratio for estriol less than the 25th
percentile and preterm birth less than 32 weeks remained statistically significant.
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The effect of 17-α-hydroxyprogesterone caproate to prevent preterm birth, stratified by the
baseline salivary concentrations of progesterone and estriol, is presented in Figure 1. The drug
reduced the occurrence of preterm birth, regardless of baseline progesterone or estriol, and the
reduction afforded did not differ significantly according to the baseline value of either hormone
(Breslow-Day P value for interaction = .77 for progesterone, .72 for estriol).
In the longitudinal analysis, mean salivary concentrations of progesterone and estriol and the
estriol/progesterone ratio by week of gestation as well as their predicted trajectories are
presented according to treatment group in Figure 2.
Progesterone concentration increased with gestational age in both groups, but the trajectory of
salivary progesterone did not differ between women assigned to 17OHPC (56 pg/L per week;
95% confidence interval [CI], 45–65) or to placebo (43 pg/L per week; 95% CI, 35–51; P for
interaction = .38). However, there was a statistically significant difference in the trajectory of
the rise in salivary estriol according to treatment group.
Although salivary estriol rose in both groups as pregnancy progressed, the rise in estriol was
significantly less among women assigned to receive 17OHPC (0.051 ng/L per week; 95% CI,
0.038–0.063) than to placebo (0.069ng/L per week; 95% CI, 0.057–0.080; P for interaction = .
013).
As a result of these changes, the estriol/progesterone ratio differed significantly between the
2 groups as pregnancy progressed. The ratio rose in the placebo group with advancing gestation
(3.9 × 10−5 ng/pg per week; 95% CI, 1.5–6.3), but in the 17OHPC group, the trajectory was
essentially flat (−3.1 × 10−6 ng/pg per week; 95% CI, −1.8 to + 1.2). It was not possible to
calculate a P value for the entire treatment course because the statistical model failed to
converge. However, the difference in trajectory between the 17OHPC and placebo groups was
significant over the first 8 weeks of treatment (P for interaction = .003).
Comment
Contrary to our hypotheses, we did not find either reduced salivary progesterone or elevated
estriol concentration at study entry (16–23 weeks’ gestation) to be associated with preterm
birth. In fact, we found statistically significant associations between elevated salivary
progesterone and increased risk of birth at less than 35 weeks’ gestation. We also noted
statistically significant associations between reduced salivary estriol and increased risk of birth
at less than 35 and 32 weeks’ gestation. We also found that the beneficial effect of 17OHPC
in reducing preterm birth was not statistically different according to baseline salivary
concentrations of either progesterone or estriol. However, we noted that compared with
placebo, 17OHPC supplementation blunted the rise in salivary estriol and eliminated the rise
in the estriol/progesterone ratio, with advancing gestation.
Although salivary progesterone concentrations are reflective of the biologically active levels
of free progesterone in serum,7 our failure to find an association between reduced baseline
salivary progesterone and preterm birth agrees with reports noting that serial plasma
progesterone concentrations did not predict preterm delivery.4 Nevertheless, there is evidence
that in humans the progesterone withdrawal that triggers normal labor is a functional
withdrawal within the uteroplacental unit, caused by local inactivation of progesterone, change
in the ratio of receptor isoforms, or other mechanisms.17 However, measurements at 16–20
weeks might not be reflective of changes occurring later in pregnancy.
Contrary to our hypothesis, we found that 17OHPC supplementation did not have an impact
on the trajectory of salivary progesterone. This is in agreement with Reijnders et al,18 who
reported that 17OHPC elevated serum progesterone by 20%, which was not statistically
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significant. However, we found that 17OHPC impacted the trajectory of salivary estriol as
pregnancy progressed. This trajectory may be of importance, given that salivary estriol and the
estriol/progesterone ratio rise throughout gestation, and that in particular, the estriol/
progesterone ratio rises dramatically immediately before term19 and preterm20 labor. In
addition, 2 consecutively elevated salivary estriol measurements have been strongly associated
with impending preterm delivery.21
Because estriol derives from dehydroepiandrosterone sulfate (DHEAS) produced by the fetal
adrenal and modified by the fetal liver and placenta, rather than the mother,22 this raises the
possibility that 17OHPC prevents preterm birth by acting on the fetus and placenta.
Alternatively 17OHPC might have a direct impact on fetal adrenal function. In normal
pregnancy, 17-α-hydroxyprogesterone is produced by the placenta from 17-α-hydroxy-Δ5
pregnenolone sulfate, a product of the fetal adrenal. The latter is an also intermediary in the
production of DHEAS, which itself is ultimately converted to estriol. Placental 17-α-
hydroxyprogesterone is in turn utilized by the fetal adrenal to produce cortisol.23-25
Because 17OHPC crosses the placenta,26 it might prevent preterm birth by providing a
downstream intermediary for fetal cortisol production and increasing the fetal adrenal’s
efficiency in producing cortisol. This in turn would suppress its production of DHEAS and
ultimately reduce the placenta’s production of estriol. Such a mechanism might explain the
finding that 17OHPC failed to prevent preterm birth in twins,27 in which the primary stimulus
for labor may be uterine distention,28 rather than fetal adrenal activity.
Our study has several limitations. The number of women analyzed was determined by available
resources. A formal sample size calculation for a longitudinal analysis would require
knowledge of both the between- and within-woman variation in salivary hormones. We were
unable to find such data, and therefore, we did not estimate a sample size a priori. We did not
obtain biospecimens other than maternal saliva. In particular, we did not have a means to assess
local hormone changes in vaginal/cervical fluid or to assess changes in progesterone receptor
isoforms in the placenta or fetal membranes. Similarly, we did not obtain maternal serum or
plasma. We also did not collect systematic data on cervical status or uterine contractility, so
we cannot determine what effect 17OHPC might have had on these organs. Nor did we collect
data on the time of day when the saliva was collected. Although there is no reason to suspect
systematic differences between 17OHPC and placebotreated women in the time of collection,
lack of knowledge of time of sample collection is likely to be a source of random error.
Determining the effect of 17OHPC supplementation on these factors and its potential impact
on the fetoplacental unit are promising avenues of further research.
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FIGURE 1. Preterm birth by treatment (17P/placebo) and baseline salivary progesterone and
estriol percentiles
Klebanoff. Salivary progesterone and estriol among pregnant women treated with 17-α-
hydroxyprogesterone caproate or placebo. Am J Obstet Gynecol 2008.
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FIGURE 2. Weekly values of salivary progesterone, estriol, and the progesterone/estriol ratio
according to treatment group
Weekly values of salivary progesterone (A), estriol (B), and the progesterone/estriol ratio (C)
according to treatment group. P value for difference in slope between drug- and placebo-treated
women = .38 for progesterone, .013 for estriol, and .003 for progesterone/estriol ratio.
Klebanoff. Salivary progesterone and estriol among pregnant women treated with 17-α-
hydroxyprogesterone caproate or placebo. Am J Obstet Gynecol 2008.
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